H Barton Grossman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Detection of bladder cancer using a point-of-care proteomic assay
    H Barton Grossman
    Department of Urology, M D Anderson Cancer Center, Houston, Tex 77030, USA
    JAMA 293:810-6. 2005
  2. ncbi request reprint Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study
    H Barton Grossman
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Oncol Rep 16:807-10. 2006
  3. ncbi request reprint Chemoprevention of bladder cancer
    H Barton Grossman
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Urology 67:19-22; discussion 23-4. 2006
  4. ncbi request reprint If cystectomy is insufficient, what is an urologist to do?
    H Barton Grossman
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 21:475-8. 2003
  5. ncbi request reprint The use of urine-based biomarkers in bladder cancer
    H Barton Grossman
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Urology 67:62-4. 2006
  6. ncbi request reprint Improving the management of bladder cancer with fluorescence cystoscopy
    H Barton Grossman
    Department of Urology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA
    J Environ Pathol Toxicol Oncol 26:143-7. 2007
  7. ncbi request reprint Selective COX-2 inhibitors as chemopreventive and therapeutic agents
    H Barton Grossman
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Drugs Today (Barc) 39:203-12. 2003
  8. ncbi request reprint Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness
    A Karim Kader
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:2614-20. 2007
  9. pmc Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection
    Hong Seok Park
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 100:1401-11. 2008
  10. pmc Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009

Research Grants

  1. TRAINING OF ACADEMIC UROLOGIC ONCOLOGISTS
    H Grossman; Fiscal Year: 2007

Detail Information

Publications96

  1. ncbi request reprint Detection of bladder cancer using a point-of-care proteomic assay
    H Barton Grossman
    Department of Urology, M D Anderson Cancer Center, Houston, Tex 77030, USA
    JAMA 293:810-6. 2005
    ..Urine tests are frequently part of an evaluation, but have either been nonspecific for cancer or required specialized analysis at a laboratory...
  2. ncbi request reprint Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study
    H Barton Grossman
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Oncol Rep 16:807-10. 2006
    ..48; p=0.15], but there was no difference in progression-free survival (HR=1.02; p=0.93). The enumeration of tumor microvessels did not provide prognostic information...
  3. ncbi request reprint Chemoprevention of bladder cancer
    H Barton Grossman
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Urology 67:19-22; discussion 23-4. 2006
    ..This review discusses chemoprevention of bladder cancer and focuses on the drugs used in chemoprevention investigations and clinical study design...
  4. ncbi request reprint If cystectomy is insufficient, what is an urologist to do?
    H Barton Grossman
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 21:475-8. 2003
    ..The most critical issue in multimodal therapy is patient selection. The choice of neoadjuvant or adjuvant therapy will depend on clinical circumstances, resources, and patient and physician preferences...
  5. ncbi request reprint The use of urine-based biomarkers in bladder cancer
    H Barton Grossman
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Urology 67:62-4. 2006
  6. ncbi request reprint Improving the management of bladder cancer with fluorescence cystoscopy
    H Barton Grossman
    Department of Urology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA
    J Environ Pathol Toxicol Oncol 26:143-7. 2007
    ..This report summarizes some of the recent studies of fluorescence cystoscopy in bladder cancer...
  7. ncbi request reprint Selective COX-2 inhibitors as chemopreventive and therapeutic agents
    H Barton Grossman
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Drugs Today (Barc) 39:203-12. 2003
    ..A number of studies are now investigating the use of COX-2 inhibitors to prevent or treat a number of different cancers. These ongoing trials will determine whether these agents are useful in the treatment of cancer...
  8. ncbi request reprint Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness
    A Karim Kader
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:2614-20. 2007
    ..MMP levels are elevated in bladder cancer patients correlating with more advanced stage. We tested whether polymorphisms in MMP genes modify the risk of bladder cancer invasiveness and whether smoke exposure modifies this risk...
  9. pmc Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection
    Hong Seok Park
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 100:1401-11. 2008
    ..We examined whether AURKA gene amplification is a biomarker for the detection of bladder cancer...
  10. pmc Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009
    ....
  11. ncbi request reprint Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
    Gordon A Brown
    Department of Urology, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA
    BJU Int 98:1176-80. 2006
    ..To evaluate factors associated with disease recurrence and survival in patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma (UUT-TCC) in one centre over an 18-year period...
  12. pmc Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center
    Siobhan P Lynch
    Department of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Eur Urol 64:307-13. 2013
    ..Small cell urothelial carcinoma (SCUC) is a rare, aggressive malignancy with a propensity for early microscopic metastases. Data suggest that neoadjuvant chemotherapy may lead to improved survival compared with initial surgery...
  13. pmc Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients
    Meng Chen
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Carcinogenesis 31:1387-91. 2010
    ..These findings warrant further replication in independent populations and may provide information on disease management and development of target therapies...
  14. ncbi request reprint Organ preservation for muscle-invasive bladder cancer by transurethral resection
    Dan Leibovici
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Urology 70:473-6. 2007
    ..To determine the feasibility of bladder preservation using transurethral resection for patients with muscle-invasive cancer and to determine the proportion of patients with muscle-invasive disease who would be eligible for this approach...
  15. ncbi request reprint Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:62-7. 2007
    ..Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience...
  16. pmc A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 119:540-7. 2013
    ..Sequential chemotherapy also has not been well studied in the neoadjuvant setting. The authors explored sequential neoadjuvant ifosfamide-based chemotherapy in a patient cohort at high risk of noncurative cystectomy...
  17. doi request reprint Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, Urology, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:2592-7. 2009
    ..We now report results from the first phase II clinical trial developed exclusively for SCUC, to our knowledge...
  18. doi request reprint Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition
    Hushan Yang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2236-44. 2008
    ..Compelling evidence has indicated that inflammation plays an important role in cancer development. We sought to test the hypothesis that common sequence variants in the inflammation pathway modulate bladder cancer risk...
  19. ncbi request reprint Case-control analysis of dietary folate and risk of bladder cancer
    Matthew B Schabath
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Nutr Cancer 53:144-51. 2005
    ..These data may have important implications for cancer prevention; however, large, hypothesis-driven, population-based clinical trials will be required to confirm these findings...
  20. pmc P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors
    Wassim Kassouf
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Eur Urol 52:769-74. 2007
    ..To improve our understanding of its significance in a contemporary series, we performed an outcomes analysis of this cohort of patients...
  21. pmc Modulation of DNA damage/DNA repair capacity by XPC polymorphisms
    Yimin Zhu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    DNA Repair (Amst) 7:141-8. 2008
    ..16, P=0.0009). The haplotypes "T-A" (in the order of Ala499Val-PAT-Lys939Gln) was associated with the lowest DNA damages. Our results suggested that the DRC of host cells might be modulated by specific XPC polymorphisms...
  22. ncbi request reprint High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility
    Maosheng Huang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Unit 1340, 1155 Pressler Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 16:84-91. 2007
    ..02%; P < 0.001). These results support the hypothesis that genetic variants in BER genes contribute to bladder cancer risk through gene-gene and gene-environmental interactions...
  23. doi request reprint Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC
    Wassim Kassouf
    Department of Urology and the Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:121-6. 2008
    ..To compare the utility of lymph node density (LND) with TNM nodal status in predicting disease-specific survival (DSS) after radical cystectomy...
  24. doi request reprint Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma
    Surena F Matin
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:3127-34. 2010
    ....
  25. ncbi request reprint Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival
    Dan Leibovici
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1155 Pressler Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:5746-56. 2005
    ..Since chronic inflammation contributes to tumorigenesis, we hypothesized that the risk and clinical outcome of bladder cancer (BC) might be modulated by genetic variations in inflammation genes...
  26. doi request reprint Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy
    Eugene K Lee
    Department of Urology Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    BJU Int 110:E590-5. 2012
    ..Using this information, we created prognostic tools incorporating lymph node density that can be used for risk stratification, patient counselling and clinical trial design...
  27. doi request reprint Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy
    Robert S Svatek
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 76:1419-24. 2010
    ..POI is a common complication after radical cystectomy and can result in a prolonged hospital stay and delayed recovery...
  28. pmc Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes
    Xifeng Wu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Am J Hum Genet 78:464-79. 2006
    ....
  29. ncbi request reprint Projecting individualized probabilities of developing bladder cancer in white individuals
    Xifeng Wu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4974-81. 2007
    ..There has been no risk assessment model for bladder cancer (BC). We developed the first model incorporating mutagen sensitivity and epidemiologic factors to predict BC risk...
  30. pmc Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy
    Gordon A Brown
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 70:252-6. 2007
    ..To evaluate whether the clinical grade predicts the final pathologic stage in upper urinary tract transitional cell carcinoma...
  31. ncbi request reprint Polymorphisms in XPD exons 10 and 23 and bladder cancer risk
    Matthew B Schabath
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Unit 189, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 14:878-84. 2005
    ....
  32. pmc The role of radical cystectomy in patients with clinical T4b bladder cancer
    Peter C Black
    Department of Urology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 29:157-61. 2011
    ..We hypothesized that select patients might achieve durable benefit from multiagent chemotherapy and extirpative surgery...
  33. ncbi request reprint Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy
    Wassim Kassouf
    Department of Urology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Urol 176:53-7; discussion 57. 2006
    ..We evaluated its relevance in a contemporary series of patients treated with radical cystectomy and in the context of adjuvant chemotherapy...
  34. ncbi request reprint Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era
    Wassim Kassouf
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1491-5. 2006
    ..In the current study, the relevance of ECE in patients treated in the contemporary era was evaluated...
  35. ncbi request reprint Matrix metalloproteinase polymorphisms and bladder cancer risk
    A Karim Kader
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:11644-8. 2006
    ..Heavy carcinogen exposure may overwhelm some of the genetic effects of MMP polymorphisms. Our study confirms the importance of taking a multigenic pathway-based approach to risk assessment...
  36. ncbi request reprint Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer
    Yimin Zhu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 28:698-703. 2007
    ..53 (0.34-0.82) for C-A/T-A, 0.48 (0.27-0.84) for C-A/C-C, 0.18 (0.053-0.60) for C-C/C-C and 0.57 (0.36-0.90) for C+C/C+C. These results suggest that sequence variants in the XPC gene might modulate the risk of bladder cancer...
  37. ncbi request reprint Management of urethral recurrence after orthotopic urinary diversion
    Jennifer M Taylor
    Department of Urology and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 106:56-61. 2010
    ..Therapy (case series) Level of Evidence 4 OBJECTIVE To evaluate our experience with urethral recurrences in patients treated by radical cystectomy(RC) and orthotopic neobladder urinary diversion for carcinoma of the bladder...
  38. pmc Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer
    Colin P N Dinney
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 190:850-6. 2013
    ..The primary objective was to determine the safety of rAd-IFNα/Syn3. Secondary end points were demonstrated effective rAd-IFNα gene expression and preliminary evidence of clinical activity at 3 months...
  39. ncbi request reprint Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer
    Jason Gee
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 15:471-7. 2006
    ..Induction of apoptosis in all three cell lines by celecoxib was associated with downregulation of Bcl-2. These changes occur independently of COX-2 expression levels suggesting the presence of a COX-2 independent pathway...
  40. pmc Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy
    M Zak Rajput
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas
    Urology 78:61-7. 2011
    ..To determine the effect of neoadjuvant chemotherapy on the surgical outcomes in patients undergoing laparoscopic radical nephroureterectomy (LNUX) for upper urinary tract urothelial carcinoma (UTUC)...
  41. ncbi request reprint Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience
    Wassim Kassouf
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 175:2058-62. 2006
    ..Partial cystectomy is a surgical option for select patients diagnosed with urothelial carcinoma. We review our experience with partial cystectomy for muscle invasive urothelial carcinoma to assess local control and survival rates...
  42. doi request reprint Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Clin Cancer Res 14:224-9. 2008
    ..The study aims to evaluate the efficacy and toxicity of fenretinide in preventing tumor recurrence in patients with transitional cell carcinoma (TCC) of the bladder...
  43. ncbi request reprint PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer
    Motoyoshi Tanaka
    Department of Urology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Detect Prev 29:170-4. 2005
    ..These data demonstrate that PTEN gene therapy can effectively treat some prostate cancers that have genomic alterations in PTEN. In others, PTEN gene therapy combined with chemotherapy is more effective...
  44. ncbi request reprint Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk
    Hua Zhao
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1155 Hermann Pressler Boulevard, Houston, TX 77030, USA
    Int J Cancer 120:2208-13. 2007
    ..The protective effect of ITCs against bladder cancer was not modified by GSTM1, GSTT1 or NAT2 genotypes. This is the first epidemiological report that ITCs from cruciferous vegetable consumption protect against bladder cancer...
  45. ncbi request reprint Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?
    Philippe E Spiess
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Urology 67:466-71. 2006
    ..To compare treatment-related outcomes of immediate and staged urethrectomy in patients at high risk of urethral recurrence...
  46. pmc Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy
    H Barton Grossman
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    J Urol 188:58-62. 2012
    ..We assessed the impact of hexaminolevulinate fluorescence cystoscopic detection of papillary, nonmuscle invasive bladder cancer on the long-term recurrence rate...
  47. pmc A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer
    Anita L Sabichi
    Department of Medicine, Division of Hematology Oncology, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 4:1580-9. 2011
    ..Our clinical trial results do not show a clinical benefit for celecoxib in preventing NMIBC recurrence but further investigation of COX-2 inhibitors in this setting is warranted...
  48. doi request reprint Clinical model of cost of bladder cancer in the elderly
    Catherine D Cooksley
    Section of Health Services Research, Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Urology 71:519-25. 2008
    ..To develop a population-based clinical model of bladder cancer (BC) care costs and identify cost drivers...
  49. doi request reprint Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection
    Yair Lotan
    Department of Urology, University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA
    BJU Int 101:1362-7. 2008
    ..Newton, MA, USA) for the detection of bladder cancer, as this is a point-of-care assay that measures NMPs in voided urine...
  50. doi request reprint Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer
    Yuanqing Ye
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2467-74. 2008
    ..Cell cycle checkpoint regulation is crucial for the prevention of carcinogenesis in mammalian cells...
  51. doi request reprint Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer
    Hushan Yang
    Department of Epidemiology and Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 68:2530-7. 2008
    ..92-fold (1.36-2.71) increased risk (P(trend) < 0.0001). Overall, this is the first epidemiologic study showing that miRNA-related genetic variants may affect bladder cancer risk individually and jointly...
  52. ncbi request reprint The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, 77030, USA
    J Urol 175:881-5. 2006
    ..Micropapillary bladder carcinoma is a rare variant of UC. Due to paucity of data regarding treatment outcomes, patients with nonmuscle invasive micropapillary UC often receive intravesical therapy in an attempt at bladder preservation...
  53. ncbi request reprint Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence
    Hua Zhao
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:30-5. 2005
    ..Based on this, the authors hypothesized that individuals who had increased plasma levels of angiogenin were at an elevated risk for carcinoma of the urinary bladder...
  54. ncbi request reprint Surveillance for recurrent bladder cancer using a point-of-care proteomic assay
    H Barton Grossman
    Department of Urology, M D Anderson Cancer Center, Houston, Tex 77030, USA
    JAMA 295:299-305. 2006
    ..At least 50% of patients with a history of bladder cancer have recurrences, so rigorous surveillance is necessary. Cystoscopy is standard but can fail to detect some bladder cancers, so a urine test is frequently part of the evaluation...
  55. ncbi request reprint Dietary carotenoids and genetic instability modify bladder cancer risk
    Matthew B Schabath
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Nutr 134:3362-9. 2004
    ..18; 95% CI, 1.13-4.22). This study provides evidence of a preventive role for carotenoids in bladder cancer, and these data may have important implications for cancer prevention, especially for individuals susceptible to DNA damage...
  56. ncbi request reprint Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy
    Kelly N Blehm
    Department of Cancer Biology, Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4671-7. 2006
    ..The focus of this study was to determine if these alterations are present within the tyrosine kinase and ligand-binding domain of EGFR in urothelial carcinoma...
  57. pmc Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk
    Jie Lin
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 131:1892-903. 2012
    ..001). These results strongly support that high red meat intake, high intake of HCAs and carrying high number of unfavorable genotypes in the HCA metabolic pathways are associated with increased risk of BC in the study population...
  58. doi request reprint Plasma vitamins E and A and risk of bladder cancer: a case-control analysis
    Dong Liang
    Department of Pharmaceutical Sciences, Texas Southern University, Houston, TX, USA
    Cancer Causes Control 19:981-92. 2008
    ..We assessed plasma vitamin E (alpha-tocopherol, and gamma-tocopherol), vitamin A (retinol), and bladder cancer risk using data collected from a case-control study...
  59. ncbi request reprint Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer
    Aditi Hazra
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Genes Chromosomes Cancer 41:330-8. 2004
    ..04, 5.69), 5.14 (1.12, 23.59), and 21.51 (4.75, 97.34), respectively, providing increasing dose-response evidence of the locus-specific alterations. Thus, 9p21 may be a molecular target for BPDE-induced damage in bladder cancer cases...
  60. ncbi request reprint The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence
    Jian Gu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Blvd, Houston, 77030, USA
    Pharmacogenomics 6:575-84. 2005
    ..Genomic variation as a mechanism that may modify BCG efficacy is discussed in detail...
  61. ncbi request reprint Genetic polymorphism in bladder cancer
    Xifeng Wu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Front Biosci 12:192-213. 2007
    ..This review presents an overview of current molecular epidemiology of bladder cancer and provides a useful resource for understanding the pathogenesis of bladder cancer...
  62. ncbi request reprint Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study
    Jian Gu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA
    Carcinogenesis 26:1741-7. 2005
    ....
  63. pmc Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer
    Jie Lin
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1155 Hermann Pressler Boulevard, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 3:505-17. 2010
    ....
  64. ncbi request reprint Review of the M.D. Anderson experience in the treatment of bladder sarcoma
    Philippe E Spiess
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Urol Oncol 25:38-45. 2007
    ..To assess the histologic subtypes, clinical presentations, treatment approaches, and treatment-related outcomes of patients with bladder sarcoma...
  65. pmc Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin
    Hua Wei
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38533. 2012
    ..1). These results support the hypothesis that genetic variations in host oxidative stress genes in NMIBC patients may affect response to therapy with BCG...
  66. ncbi request reprint Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer
    Jian Gu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:1408-15. 2005
    ..Polymorphisms in NER genes may influence DNA repair capacity and affect clinical outcome of bladder cancer treatment...
  67. pmc Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer
    Meng Chen
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 3:1235-45. 2010
    ..05), none remained significant after multiple-comparison adjustments. Germ-line genetic variations in the Shh pathway predicted clinical outcomes of TUR and BCG for NMIBC patients...
  68. ncbi request reprint Comparative outcomes of bladder cancer
    Marylou Cardenas-Turanzas
    Section of Health Services Research, Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Obstet Gynecol 108:169-75. 2006
    ..To compare the survival of women and men with transitional cell bladder cancer...
  69. doi request reprint Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms
    Alan D Xu
    Department of Radiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    AJR Am J Roentgenol 195:959-65. 2010
    ....
  70. ncbi request reprint Bladder cancer risk as modified by family history and smoking
    Jie Lin
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:705-11. 2006
    ..The authors investigated the role of family history in association with the risk of BC...
  71. ncbi request reprint An association between NQO1 genetic polymorphism and risk of bladder cancer
    Seun Ja Park
    Department of Epidemiology, Unit 189, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Mutat Res 536:131-7. 2003
    ..78; 95% CI=1.06-3.00), but not in never smokers (OR=1.19; 95% CI=0.65-2.20). These results suggest that the NQO1 genetic polymorphism modulates bladder cancer risk, especially in men and ever smokers...
  72. ncbi request reprint Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
    H Barton Grossman
    M D Anderson Cancer Center, Houston, USA
    N Engl J Med 349:859-66. 2003
    ..We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy...
  73. ncbi request reprint Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation
    Charles J Rosser
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Gene Ther 11:273-9. 2004
    ..These findings suggest that overexpression of Bcl-2 result in radioresistance and inability of radiation to cause its typical G2M cell-cycle arrest...
  74. doi request reprint Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection
    John W Davis
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 185:79-83. 2011
    ..Our primary objective was to determine the fraction of lymph nodes yielded by robot assisted pelvic lymph node dissection...
  75. ncbi request reprint Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells
    Motoyoshi Tanaka
    Department of Urology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Oncol Rep 11:537-41. 2004
    ..Forced expression of Cx26 suppresses the growth of prostate cancer cells and decreases the expression of Bcl-2. Combining Cx26 gene therapy with doxorubicin results in greater growth suppression...
  76. ncbi request reprint High-frequency endoluminal ultrasonography as an aid to the staging of upper tract urothelial carcinoma: imaging findings and pathologic correlation
    Surena F Matin
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Ultrasound Med 29:1277-84. 2010
    ..We analyzed endoluminal ultrasonography (ELUS) for evaluating renal pelvic and ureteral, or upper tract, urothelial carcinoma (UTUC)...
  77. ncbi request reprint Focus on bladder cancer
    Colin P N Dinney
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX USA
    Cancer Cell 6:111-6. 2004
  78. ncbi request reprint Neoadjuvant chemotherapy for bladder cancer
    Randall Millikan
    Department of Genitourinary Medical Oncology, Genitourinary Center, University of Texas, M D Anderson Cancer Center, Houston, TX 77033, USA
    Urol Oncol 21:464-7. 2003
    ..The authors make an appeal for a biologically (in contrast to anatomically) based staging system, and urge that perioperative chemotherapy be given with standard combinations with curative intent...
  79. ncbi request reprint Clinical model of lifetime cost of treating bladder cancer and associated complications
    Elenir B C Avritscher
    Section of Health Services Research, Department of Biostatistics and Applied Mathematics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 68:549-53. 2006
    ..To estimate the lifetime cost of bladder cancer and the contribution of complications to the total costs...
  80. ncbi request reprint Methyl-CpG-binding domain 2: a protective role in bladder carcinoma
    Yong Zhu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1853-8. 2004
    ..In the current case-control study, the authors investigated the association between MBD2 expression and bladder carcinoma risk...
  81. ncbi request reprint Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study
    Linda S Elting
    Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:975-84. 2005
    ..In the current study, the authors studied these associations, emphasizing hospital factors that contribute to the volume-outcome correlation...
  82. ncbi request reprint Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder
    Jason R Gee
    Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Urol Oncol 21:266-70. 2003
    ..CK20, AN43 and PGDH decreased but COX-2 expression increased in higher stage tumors. The histologic phenotype of these cancers is reflected in their expression of these proteins and is modified further as tumors progress in stage...
  83. ncbi request reprint Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, Box 427, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    J Clin Oncol 21:2247-53. 2003
    ..We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer...
  84. ncbi request reprint Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology, and Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    J Urol 172:481-4. 2004
    ..Neuroendocrine tumors of the bladder comprise a small subset of all bladder tumors. To improve our understanding of this tumor and define outcomes with current management, we performed a retrospective review of these cases...
  85. ncbi request reprint Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study
    Jie Lin
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Carcinogenesis 25:1639-47. 2004
    ..These results have important implications for cancer prevention in susceptible populations...
  86. ncbi request reprint Pathologic evaluation of radical cystectomy specimens: a cooperative group report
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:2470-5. 2004
    ..Their objective was to determine whether current practices conform to suggested pathology practice guidelines for reporting on radical cystectomy and pelvic lymph node specimens...
  87. ncbi request reprint N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines
    Changping Zou
    Department of Obstetrics and Gynecology, The University of Texas Houston Medical School, Houston, TX 77030, USA
    Cancer Lett 180:131-7. 2002
    ..Once our results are verified and replicated by other investigators, 4-HPR may have a potential clinical implication in effectively treating bladder cancer in combination with low-gamma-irradiation therapy...
  88. ncbi request reprint Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression
    Anita Sabichi
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 175:1133-7. 2006
    ..Cell lines have become an essential component for the investigation of cancer. We have developed a panel of cell lines derived from human urothelial cancers and we describe some of their important characteristics...
  89. ncbi request reprint Death receptor 4 and bladder cancer risk
    Aditi Hazra
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 63:1157-9. 2003
    ....
  90. ncbi request reprint Neoadjuvant chemotherapy for bladder cancer
    Peter C Black
    Department of Urology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX 77030, USA
    World J Urol 24:531-42. 2006
    ..Finally, a risk-adapted approach to neoadjuvant chemotherapy is presented, whereby the highest risk patients are offered treatment while those unlikely to benefit are spared the treatment-related toxicity...
  91. ncbi request reprint Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study
    Leizhen Zheng
    Department of Epidemiology Unit 189, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer Lett 202:61-9. 2003
    ..Further studies are warranted to elucidate the function of this SULT1A1 polymorphism with regard to organ specificity, gene-environment interactions, and the gender-related difference we observed...
  92. ncbi request reprint Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture
    Joseph M Unger
    Southwest Oncology Group Statistical Center and the Puget Sound Oncology Consortium, Seattle, WA, USA
    J Clin Oncol 21:246s-252s. 2003
    ..Meanwhile the prevention of cancer has received less attention...
  93. ncbi request reprint Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    Cancer 110:764-9. 2007
    ..Nonbilharzial squamous cell carcinoma (SCC) of the bladder is a rare entity in the Western hemisphere. To further understanding of its natural history, a contemporary experience with management and outcome of this disease was reviewed...
  94. ncbi request reprint Surgical factors influence bladder cancer outcomes: a cooperative group report
    Harry W Herr
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 22:2781-9. 2004
    ..We evaluated whether surgical factors from patients enrolled onto the study predicted bladder cancer outcomes...
  95. ncbi request reprint Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells
    Changping Zou
    Department of Obstetrics and Gynecology, University of Arizona, Tucson, AZ 85724, USA
    Front Biosci 11:2007-16. 2006
    ..However, 4-HPR was effective at a concentration at least 10 microM. The in vitro results suggested the higher dose of 4-HPR in chemoprevention trial be considered...
  96. ncbi request reprint DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC
    Ihor S Sawczuk
    Columbia University, Urology Department, 161 Fort Washington Ave, New York, NY 10032, USA
    Urol Oncol 7:185-90. 2002
    ..A prospective clinical study was conducted to assess the ability of the DD23 murine monoclonal antibody to enhance detection of bladder cancer in routine alcohol fixed urine cytology samples...

Research Grants2

  1. TRAINING OF ACADEMIC UROLOGIC ONCOLOGISTS
    H Grossman; Fiscal Year: 2007
    ..Post-doctoral fellows have the opportunity to work closely with clinicians during their training. This association with outstanding clinicians will help integrate their future research into translational efforts. ..